Posts Tagged: Alzheimer’s disease
Ontario Government Invests $1 Million in Toronto’s Neuroscience Catalyst Consortium
Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies
TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer's disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million ...
Read more
Dr. Raphael Hofstein in Biotechnology Focus: It’s time to declare an end to Canada’s two research solitudes
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by Dr. Raphael Hofstein, MaRS Innovation's president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.
The article explores the way research focused on discovery and commercialization are often viewed or positioned as competitors within the funding ecosystem and the need to align their goals:
The time of Canada’s French and English solitudes may be past, as Governor General Michaëlle Jean notably stated when she took office ...
Read more
Dr. Hofstein’s Op-Ed for The Hill-Times, “Biotechnology research: A knowledge economy”
This op-ed on Canadian biotechnology and the knowledge economy appeared in The Hill-Times (subscription required), Canada's politics and government newsweekly, September 9:
Obesity, cancer, heart disease and stroke, diabetes, Parkinson’s disease, Alzheimer’s, or the more general stresses of an aging population: no matter which area of concern holds our collective gaze from moment to moment, improving health outcomes and healthcare is the No. 1 challenge for the world’s economy.
Canada has the holistic approach and translational research necessary to address health care’s pervasive ...
Read more
Business Without Borders features Encycle Therapeutics, Raphael Hofstein
Encycle Therapeutics, a MaRS Innovation spin-off company, was featured by Business Without Borders' High Tech section in a Q&A profile with MI's President and CEO, Raphael Hofstein.
Here's an excerpt:
Business Without Borders (BWB): What makes Encycle’s technology so promising?
Raphael Hofstein (RH): Proteins are made of smaller units called peptides, usually existing as linear chains. If they get into the bloodstream, they get degraded rapidly by enzymes and they find it very difficult to get into cells of the body. What we want ...
Read more